RESUMO
Abstract Objectives: describe the profile of medication use and adherence, and the association with clinical and sociodemographic characteristics of high-risk pregnant women attended at a university hospital. Methods: cross-sectional study with data collected through a questionnaire applied on 386 pregnant women. Results: most participants were seen only by the gynecologist (75.1%), started prenatal in the first gestational trimester (86.8%), did not plan the pregnancy (61.9%), and performed an average of 8.2 (SD=4.4) prenatal consultations. The most frequent diagnoses were arterial hypertension (20.5%) and diabetes mellitus (19.7%). Prevalence of medication use was 99.7%, with an average of 5.1 (SD=2.1) medication per woman and 12.7% self-medication. Antianemics (88.9%) and analgesics (63.2%) were the most prevalent classes and 17.9% of the women reported the use of medication with significant gestational risk. Only 36.5% were considered adherent, 32.9% declared they were unaware of the indication of the medication in use and 42% did not receive guidance on the use of the medication during pregnancy. There is no evidence of association between the number of the medication used and clinical and sociodemographic aspects. Conclusions: there is a need to develop strategies to improve the care of this population, with emphasis on strengthening multi-professional care.
Resumo Objetivos: descrever o perfil de utilização de medicamentos e de adesão, e a associação com as características clínicas e sociodemográficas de gestantes de alto risco atendidas em um hospital universitário. Métodos: trata-se de um estudo transversal com dados coletados mediante um questionário estruturado aplicado à 386 gestantes. Resultados: a maior parte das participantes era acompanhada apenas pelo ginecologista (75,1%), iniciou o pré-natal no primeiro trimestre gestacional (86,8%), não planejou a gravidez (61,9%) e realizou em média 8,2 (DP=4,4) consultas de pré-natal. Os diagnósticos mais frequentes foram hipertensão arterial (20,5%) e diabetes mellitus (19,7%). A prevalência de uso de medicamentos foi 99,7%, com média de 5,1 (DP=2,1) medicamentos por mulher e 12,7% de automedicação. Os antianêmicos (88,9%) e analgésicos (63,2%) foram as classes farmacológicas mais prevalentes e 17,9% das gestantes referiram uso de fármacos com risco gestacional relevante. Apenas 36,5% das gestantes foram consideradas aderentes ao tratamento, 32,9% declararam desconhecer a indicação dos medicamentos em uso e 42% não receberam orientações sobre o uso de medicamentos durante a gestação. Não há evidências de associação entre o número de medicamentos utilizados e os aspectos clínicos e sociodemográficos. Conclusão: é necessário desenvolver estratégias para melhorar o atendimento desta população e o uso racional de medicamentos, com ênfase no fortalecimento do cuidado multiprofssional.
Assuntos
Humanos , Feminino , Gravidez , Farmacoepidemiologia/métodos , Gravidez de Alto Risco/efeitos dos fármacos , Uso de Medicamentos , Fatores Sociodemográficos , Brasil , GestantesRESUMO
Preeclampsia still represents a life-threatening pregnancy complication, associated with severe maternal and neonatal morbidity and mortality. Low-dose Aspirin is advised to avoid preeclampsia in high-risk pregnancies worldwide. As Aspirin does not cover all women at risk, the prescription raises questions concerning optimal target population, dosage, and onset of therapy. The aim of this study was to test platelet responsiveness on Aspirin by optical aggegrometry, to gain robust biochemically assessment data of Aspirin in an obstetric cohort. 248 women at high risk for development of preeclampsia were included in the study. Aspirin-prophylaxis was administered either in 100â¯mg (nâ¯=â¯229) or 150â¯mg (nâ¯=â¯90) daily. Dosing of 100â¯mg Aspirin was maintained if testing revealed a sufficient platelet inhibition. If platelet inhibition was insufficient, dosage was increased to 150â¯mg Aspirin and re-testing was advised. 91 patients (91/229â¯=â¯39.7%) presented a sufficient inhibitory Aspirin effect at a dosage of 100â¯mg, but in 138 patients LTA showed an inadequate Aspirin response (138/229â¯=â¯60.3%). In 19 women 150â¯mg Aspirin was administered as starting dose due to new recommendations. Of all women at 150â¯mg Aspirin 64 did not properly respond (35.4%). The overall rate of sufficient responding women regardless the Aspirin dose was 64.6%. This study demonstrates still an insufficient inhibition of platelet aggregation in about 1/3 of women even with a dosage of 150â¯mg Aspirin daily, who might potentially benefit from further increase. These data show, that there is a need for further research to allow a personalized approach for individualized Aspirin therapy, maximizing the preventive benefit for mother and child.
Assuntos
Aspirina/administração & dosagem , Plaquetas/efeitos dos fármacos , Inibidores da Agregação Plaquetária/administração & dosagem , Pré-Eclâmpsia/prevenção & controle , Adulto , Plaquetas/imunologia , Relação Dose-Resposta a Droga , Feminino , Humanos , Agregação Plaquetária/efeitos dos fármacos , Agregação Plaquetária/imunologia , Pré-Eclâmpsia/sangue , Pré-Eclâmpsia/imunologia , Gravidez , Gravidez de Alto Risco/sangue , Gravidez de Alto Risco/efeitos dos fármacos , Gravidez de Alto Risco/imunologia , Fatores de RiscoRESUMO
PURPOSE: Pregnancies in women with essential thrombocythemia (ET) are at a higher risk for obstetrical complications. Acetylsalicylic acid (ASA) and low-molecular weight heparin (LMWH) are common options to prevent miscarriages and maternal complications, whereas interferon alpha (IFN) seems to be the cytoreductive therapy of choice. This retrospective study analyzes the largest number of IFN pregnancies to date in terms of outcome and safety. METHODS: Data of 34 high-risk pregnancies in 23 women presenting at the University hospitals of Minden and Jena from 01-Jun-2007 to 01-Jun-2020 were collected. Reasons defining high-risk ET pregnancy in all 23 patients were: Thrombosis (n = 9) or severe hemorrhage (n = 2) in history, platelet count ≥ 1500 × 103/µl (n = 8) or severe microcirculatory disturbances not completely responding to ASA (n = 4). RESULTS: Without the use of IFN, live birth rate was 60% (6/10), however, after the use of IFN live birth rate increased to 73.5% (25/34 pregnancies). Nine pregnancies ended in miscarriages (9/34; 26.5%); all of them spontaneous abortions. Live birth rate significantly improved with ASA (90% versus 50%, p = 0.0168), however, if ASA and LMWH was added (n = 14), live birth rate was 100%. IFN compound (PEGylated versus standard IFN) and JAK2-driver mutation had no impact on pregnancy outcome. One major maternal complication occurred as a major peripartal bleeding after abortion curettage. CONCLUSION: IFN was associated with an encouraging live birth rate of 73.5% with no fatal maternal events and manageable side effects.
Assuntos
Interferon-alfa/uso terapêutico , Gravidez de Alto Risco/efeitos dos fármacos , Trombocitemia Essencial/tratamento farmacológico , Aborto Espontâneo/metabolismo , Aborto Espontâneo/prevenção & controle , Adulto , Aspirina/uso terapêutico , Feminino , Heparina de Baixo Peso Molecular/uso terapêutico , Humanos , Janus Quinase 2/metabolismo , Contagem de Plaquetas/métodos , Gravidez , Resultado da Gravidez , Gravidez de Alto Risco/metabolismo , Estudos Retrospectivos , Trombocitemia Essencial/metabolismo , Adulto JovemRESUMO
INTRODUCTION: The benefit of aspirin in preventing preeclampsia is increasingly recognized; however, its mechanism of action remains unclear. Nonobstetric studies have described an anti-inflammatory effect of aspirin through the 15-epilipoxin-A4 pathway (aspirin-triggered lipoxin [ATL]). However, the anti-inflammatory mechanism of aspirin in the prevention of preeclampsia remains unknown. OBJECTIVE/HYPOTHESIS: To examine (1) the difference in longitudinal endogenous lipoxin-A4 (En-Lipoxin-A4) concentration in low-risk (LR) and high-risk (HR) pregnancies, and (2) the effect of aspirin on endogenous ATL concentration and the associated effect on cytokine profile of HR women. METHODS: Plasma from 220 HR women was collected at 12, 16, 20, 24, 28, 32, and 36 weeks of gestation. Adherence to aspirin was biochemically verified. Plasma En-Lipoxin-A4 and ATL concentrations were analyzed using liquid chromatography mass spectrometry, and cytokines, interleukin (IL)-10, tumor necrosis factor-α, interferon-γ, IL-8, and IL-1ß, with the high-sensitivity multibead Luminex® assay. RESULTS: HR women have up to 70% lower plasma concentration of En-Lipoxin-A4 (P < 0.001) than LR women. HR women with adequate aspirin adherence (HR-AA) (n = 82) had higher plasma concentration of ATL (P < .001), lower concentration of IL-8 from 16 to 36 weeks of gestation (P < .001), and increased IL-10 concentration from 16 to 28 weeks of gestation (P = .03) compared with high-risk women who were not on aspirin (HR-NA). HR-AA who did not develop preeclampsia had higher plasma En-lipoxin-A4 (P < .001), ATL (P = .02), and IL-10 concentrations (P < .001) with lower IL-8 concentration (P = .004) than HR women who developed preeclampsia. DISCUSSION: Plasma concentration of En-Lipoxin-A4 is lower in HR women than in LR controls. Adequate adherence with aspirin results in an increase in ATL and IL-10 with reduced IL-8 plasma concentration. This study suggests a potential anti-inflammatory role of aspirin through the ATL pathway with prophylactic aspirin in HR pregnant women.
Assuntos
Aspirina/uso terapêutico , Lipoxinas/metabolismo , Pré-Eclâmpsia/prevenção & controle , Adulto , Aspirina/farmacologia , Estudos de Casos e Controles , Quimioprevenção/métodos , Estudos de Coortes , Feminino , Humanos , Lipoxinas/sangue , Estudos Longitudinais , Redes e Vias Metabólicas/efeitos dos fármacos , Redes e Vias Metabólicas/fisiologia , Pré-Eclâmpsia/sangue , Pré-Eclâmpsia/metabolismo , Gravidez , Gravidez de Alto Risco/efeitos dos fármacos , Gravidez de Alto Risco/metabolismoRESUMO
OBJECTIVE: To compare maternal haemodynamics in women at low and high risk for preterm pre-eclampsia (PE), and between those at high risk who are randomised to aspirin or placebo. DESIGN: Prospective, longitudinal observational study. SETTING: Maternity units in six UK hospitals. POPULATION: Women participating in the Aspirin for Prevention of Preterm Pre-eclampsia (ASPRE) trial. The population comprised three groups of women: low risk for preterm PE (n = 1362), high risk for preterm PE treated with aspirin (n = 208) and high risk for preterm PE on placebo (n = 220). METHODS: Women had four visits during pregnancy: 11-14, 19-24, 30-34, and 35-37 weeks' gestation. Blood pressure was measured with a device validated for pregnancy, and PE and maternal haemodynamics were assessed with a bioreactance monitor at each visit. A multilevel linear mixed-effects analysis was performed to examine longitudinal changes of maternal haemodynamic variables, controlling for demographic characteristics, past medical history and medication use. MAIN OUTCOME MEASURES: Longitudinal changes of cardiac output (CO), mean arterial pressure (MAP), and peripheral vascular resistance (PVR). RESULTS: The low-risk group demonstrated the expected changes with an increase in CO and reduction in MAP and PVR, with a quadratic change across gestation. In contrast, the high-risk groups had a declining CO, and higher MAP and PVR during pregnancy. The administration of aspirin did not appear to affect maternal haemodynamics. CONCLUSIONS: Women screened as high risk for preterm PE have a pathological cardiac adaptation to pregnancy and the prophylactic use of aspirin (150 mg oral daily from the first trimester) in this group may not alter this haemodynamic profile. TWEETABLE ABSTRACT: In women at high risk of pre-eclampsia, prophylactic use of aspirin may not alter the impaired maternal cardiac adaptation.
Assuntos
Aspirina/uso terapêutico , Débito Cardíaco/efeitos dos fármacos , Inibidores da Agregação Plaquetária/uso terapêutico , Pré-Eclâmpsia/prevenção & controle , Gravidez de Alto Risco/efeitos dos fármacos , Adulto , Pressão Arterial/efeitos dos fármacos , Pressão Arterial/fisiologia , Débito Cardíaco/fisiologia , Feminino , Idade Gestacional , Humanos , Estudos Longitudinais , Pré-Eclâmpsia/tratamento farmacológico , Gravidez , Gravidez de Alto Risco/fisiologia , Estudos Prospectivos , Fatores de Risco , Resultado do Tratamento , Resistência Vascular/efeitos dos fármacos , Resistência Vascular/fisiologiaRESUMO
This prospective study examined the associations between the levels of eight urinary phthalate metabolites in 599 couples and in vitro fertilization (IVF) outcomes. We used log-binomial multivariate regression to estimate relative risks (RR) for the association between phthalate concentration and IVF binary outcomes (fertilization rate >50%, biochemical pregnancy, clinical pregnancy and live birth) for each woman after adjusting the model for the concentration in a male partner and each relevant confounders. RR was expressed per unit increase in log-transformed urinary metabolite concentration. The percentage of bis-2-ethylhexyl phthalate (DEHP) metabolites excreted as mono-2-ethylhexyl phthalate (MEHP) was calculated as %MEHP. Urinary MEHP in women was associated with an increased risk of biochemical pregnancy (RRâ¯=â¯1.35; pâ¯=â¯0.04), failed clinical pregnancy (RRâ¯=â¯1.56; pâ¯=â¯0.006) and live birth (RRâ¯=â¯1.54; pâ¯=â¯0.011). An increase in monoethyl phthalate was associated with a high risk of failed clinical pregnancy (RRâ¯=â¯1.25; pâ¯=â¯0.03) and live birth (RRâ¯=â¯1.35; pâ¯=â¯0.006). An increase in %MEHP was associated with an increase in the risk of biochemical pregnancy (RRâ¯=â¯1.55; pâ¯=â¯0.05), failed clinical pregnancy (RRâ¯=â¯1.73; pâ¯=â¯0.02) and live birth (RRâ¯=â¯1.65; pâ¯=â¯0.046). Our results demonstrated that exposure to some phthalates may adversely affect IVF outcomes, particularly when couples' exposure was jointly modeled, emphasizing the importance of a couple-based approach in assessing fertility outcomes. The associations between IVF outcomes and DEHP metabolites were stronger in women whose %MEHP was >75th percentile which may be due to their less efficient metabolism and excretion of DEHP and/or MEHP.
Assuntos
Exposição Ambiental/efeitos adversos , Fertilidade/efeitos dos fármacos , Fertilização in vitro/efeitos dos fármacos , Ácidos Ftálicos/toxicidade , Ácidos Ftálicos/urina , Resultado da Gravidez , Adolescente , Adulto , Feminino , Humanos , Nascido Vivo , Masculino , Pessoa de Meia-Idade , Gravidez , Gravidez de Alto Risco/efeitos dos fármacos , Estudos Prospectivos , Adulto JovemRESUMO
OBJECTIVES: The aim of this study was to report number, type and severity of prescribing errors and pharmacist interventions in high-risk pregnant and postpartum women. DESIGN: A prospective cross-sectional, observational study. SETTING: A high-risk obstetric inpatient unit of a Women's Hospital in Brazil. PARTICIPANTS: About 1826 electronic prescriptions for 549 women in the high-risk obstetrics inpatient unit were included. INTERVENTIONS: When the pharmacist detected potential prescribing errors, interventions were suggested. MAIN OUTCOME MEASURES: Prescriptions were evaluated by clinical pharmacist to identify the type, frequency and severity of prescribing errors and rate of clinical pharmacist intervention acceptance in a high-risk obstetric inpatient. RESULTS: A total of 1826 prescriptions were reviewed with 128 errors (7.0%). The most frequent errors were drug interaction (43.8%), incorrect frequency (21.5%) and improper dose (13.1%). One-hundred and sixty-eight interventions were made by pharmacists, 98.8% of which were accepted by prescribers. Higher maternal age (OR 1.0 (95%CI 1.0-1.1)), higher number of prescribed medications (OR 1.2 (95%CI 1.1-1.3)), obstetric conditions (OR 2.2 (95%CI 1.4-3.3)) and non-breastfeeding postpartum women (OR 3.9 (95% CI 2.5-6.1)) were the independent factors associated with prescribing errors identified through multivariate analysis. CONCLUSIONS: The most common prescription errors related to drug interactions, incorrect frequency and higher number of prescribed medications. The rate of pharmacist acceptance intervention was high.
Assuntos
Erros de Medicação/prevenção & controle , Serviço de Farmácia Hospitalar/métodos , Período Pós-Parto/efeitos dos fármacos , Gravidez de Alto Risco/efeitos dos fármacos , Fatores Etários , Brasil , Estudos Transversais , Feminino , Hospitais de Ensino , Humanos , Pacientes Internados , Farmacêuticos , Gravidez , Estudos ProspectivosRESUMO
Elevated blood pressure in young adulthood is an early risk marker for cardiovascular disease. Despite a strong biological rationale, little research has evaluated whether incremental increases in preconception blood pressure have early consequences for reproductive health. We evaluated preconception blood pressure and fecundability, pregnancy loss, and live birth in the EAGeR trial (Effects of Aspirin on Gestational and Reproduction; 2007-2011), a randomized clinical trial of aspirin and reproductive outcomes among 1228 women attempting pregnancy with a history of pregnancy loss. Systolic and diastolic blood pressure were measured during preconception in the first observed menstrual cycle and in early pregnancy and used to derive mean arterial pressure. Fecundability was assessed as number of menstrual cycles until pregnancy, determined through human chorionic gonadotropin testing. Pregnancy loss included both human chorionic gonadotropin-detected and clinical losses. Analyses adjusted for treatment assignment, age, body mass index, race, marital status, smoking, parity, and time since last loss. Mean preconception systolic and diastolic blood pressure were 111.6 mm Hg (SD, 12.1) and 72.5 (SD, 9.4) mm Hg. Risk of pregnancy loss increased 18% per 10 mm Hg increase in diastolic blood pressure (95% confidence interval, 1.03-1.36) and 17% per 10 mm Hg increase in mean arterial pressure (95% confidence interval, 1.02-1.35) in adjusted analyses. Findings were similar for early pregnancy blood pressure. Preconception blood pressure was not related to fecundability or live birth in adjusted analyses. Findings suggest that preconception blood pressure among healthy women is associated with pregnancy loss, and lifestyle interventions targeting blood pressure among young women may favorably impact reproductive health. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00467363.
Assuntos
Aborto Espontâneo/epidemiologia , Aspirina/administração & dosagem , Hipertensão/prevenção & controle , Resultado da Gravidez , Gravidez de Alto Risco/efeitos dos fármacos , Aborto Espontâneo/prevenção & controle , Adulto , Pressão Sanguínea/efeitos dos fármacos , Pressão Sanguínea/fisiologia , Determinação da Pressão Arterial/métodos , Estudos de Coortes , Feminino , Fertilidade , Humanos , Hipertensão/diagnóstico , Nascido Vivo , Cuidado Pré-Concepcional/métodos , Gravidez , Estudos Prospectivos , Medição de RiscoRESUMO
Statins seem to positively influence the inflammatory, anti-angiogenic milieu of pregnancies with underlying placental ischemia by their pleiotropic effects. This might prevent, ameliorate and delay preeclampsia. To confirm the benefits of pravastatin on gestational age at birth as well as clinic and angiogenic markers in pregnancies at high-risk for preeclampsia, the Department of Obstetrics at the University Hospital Leipzig plans a randomized, double-blinded, placebo-controlled feasibility study.
Assuntos
Anticolesterolemiantes/uso terapêutico , Pravastatina/uso terapêutico , Pré-Eclâmpsia/prevenção & controle , Gravidez de Alto Risco/efeitos dos fármacos , Anticolesterolemiantes/efeitos adversos , Método Duplo-Cego , Estudos de Viabilidade , Feminino , Desenvolvimento Fetal/efeitos dos fármacos , Idade Gestacional , Humanos , Recém-Nascido , Neovascularização Fisiológica/efeitos dos fármacos , Pravastatina/efeitos adversos , Gravidez , Resultado da Gravidez , Segundo Trimestre da Gravidez , Fluxo Sanguíneo Regional/efeitos dos fármacos , Ultrassonografia Pré-Natal , Útero/irrigação sanguíneaRESUMO
Uso de drogas ilícitas como maconha, cocaína e crack durante a gestação tornou-se problema de saúde pública. O uso de drogas durante a gestação pode provocar má-formação, prematuridade, baixo peso, diminuição do perímetro cefálico, morte súbita. Aumenta a incidência de complicações como deslocamento de placenta, isquemias, infarto e morte. Conhecer os fatores de risco poderá ajudar a elaboração de programas de orientação para as gestantes e melhor conduta para os profissionais da saúde. Este estudo de revisão sistemática pesquisou nas bases de dados Bireme, Scielo, PubMed, Lilacs e Site Up to Date. A seleção levou em conta seus títulos e resumos relacionados ao assunto, no período de 2010 a 2017, utilizando os descritores drogas ilícitas/illict drug, cocaína/cocaine, gravidez/pregnancy e desenvolvimento fetal/fetal morphology. Foram encontrados 64 artigos; desses, foram selecionados 36, os mais recentes, estudos randomizados, relatos de casos e estudos coortes, os quais foram necessários para a construção do texto. Através desta análise observou-se que não existem artigos que falem diretamente sobre os riscos expostos e por qual motivo algumas pessoas, mesmo expostas aos riscos, possuem fetos normais. Portanto, novas pesquisas na área se tornam necessárias para melhor compreensão de como as drogas ilícitas interferem na formação fetal e adotar medidas profiláticas com o intuito de proteger o feto e a gestante, contribuindo para a melhoria da saúde pública.(AU)
Use of illicit drugs such as marijuana, cocaine and crack during pregnancy has become a public health problem. The use of drugs during pregnancy can cause malformation, prematurity, low weight, decreased head circumference, sudden death. It increases the incidence of complications such as placental dislocation, ischaemia, infarction and death. Knowing the risk factors can help the development of programs for counseling pregnant women and better conduct for health professionals. This systematic review study searched the Bireme, Scielo, PubMed, Lilacs and Site Up to Date databases. The selection took into account the titles and summaries related to the subject, from 2010 to 2017, using the descriptors illicit drug / illict drug, cocaine / cocaine, pregnancy / pregnancy and fetal development / fetal morphology. We found 64 articles, of which 36 were selected, the most recent, randomized studies, case reports, cohort studies, which were necessary for the construction of the text. Through this analysis it was observed that there are no articles that speak directly about the risks exposed and for which reason some people even exposed to the risks have normal fetuses. Therefore, new research in the area is necessary to better understand how illicit drugs interfere in fetal formation and adopt prophylactic measures to protect the fetus and pregnant women, contributing to the improvement of public health.(AU)
Assuntos
Humanos , Feminino , Gravidez , Drogas Ilícitas/efeitos adversos , Drogas Ilícitas/toxicidade , Gravidez de Alto Risco/efeitos dos fármacos , Transtornos Relacionados ao Uso de Substâncias/complicações , Desenvolvimento Fetal/efeitos dos fármacos , Usuários de Drogas , Complicações na Gravidez , Cuidado Pré-Natal , Cannabis/toxicidade , Fatores de Risco , Bases de Dados Bibliográficas , Cocaína Crack/toxicidade , Cocaína/toxicidade , Heroína/toxicidadeRESUMO
OBJECTIVE: To investigate factors associated with high-risk gestational diabetes (GDM) among patients with GDM. METHODS: The present retrospective study included women with singleton pregnancies diagnosed with GDM using International Association of Diabetes and Pregnancy Study Group criteria at a single tertiary perinatal care center in Japan between July 1, 2010, and October 31, 2014. High-risk GDM was defined as patients who required at least 20 units of insulin therapy a day, delivering a large-for-gestational age neonate regardless of insulin therapy, or both. Maternal characteristics and diagnostic test results were investigated to identify associations with the high-risk criteria, and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. RESULTS: Among 217 patients, 95 (43.8%) were categorized as high risk. After adjusting for confounders, a fasting plasma glucose level at diagnosis of at least 4.66 mmol/L (adjusted OR 2.88, 95% CI 1.51-5.58) and pre-pregnancy body mass index (calculated as weight in kilograms divided by the square of height in meters) of at least 24 (adjusted OR 3.27, 95% CI 1.60-6.90) were independently associated with meeting the high-risk criteria. CONCLUSION: Among Japanese patients with GDM, pre-pregnancy body mass index and fasting plasma glucose levels could be used to identify high-risk patients requiring intensive care during pregnancy.
Assuntos
Glicemia/análise , Índice de Massa Corporal , Cuidados Críticos , Diabetes Gestacional/diagnóstico , Jejum/sangue , Gravidez de Alto Risco , Adulto , Cuidados Críticos/estatística & dados numéricos , Diabetes Gestacional/sangue , Diabetes Gestacional/tratamento farmacológico , Feminino , Idade Gestacional , Humanos , Recém-Nascido , Insulina/uso terapêutico , Japão , Gravidez , Gravidez de Alto Risco/efeitos dos fármacos , Gravidez de Alto Risco/metabolismo , Estudos Retrospectivos , Fatores de RiscoRESUMO
Aspirin (acetylsalicylic acid) has been used ever since the Antiquity for its painkilling and anti-inflammatory effects. Its antiplatelet properties have then extended its indications to the field of coronaropathy and vascular cerebral disease, and finally to vascular placental disease. Aspirin has been widely prescribed since the 1980's to prevent pre-eclampsia, intra-uterine growth retardation and fetal death of vascular origin. It has also been proposed to prevent unexplained recurrent miscarriages. Its use during pregnancy is considered as safe, provided the daily doses do not exceed 100mg. Aspirin has been proven efficient to prevent pre-eclampsia and fetal growth restriction in high-risk patients. The benefits of prescribing aspirin have been demonstrated neither for vascular placental disease prevention in low risk patients, nor in cases of unexplained recurrent miscarriages.
Assuntos
Aspirina/uso terapêutico , Morte Fetal/prevenção & controle , Retardo do Crescimento Fetal/prevenção & controle , Pré-Eclâmpsia/prevenção & controle , Feminino , Humanos , Gravidez , Gravidez de Alto Risco/efeitos dos fármacosRESUMO
BACKGROUND: Preterm birth is the primary cause of infant death worldwide. A short cervix in the second trimester of pregnancy is a risk factor for preterm birth. In specific patient cohorts, vaginal progesterone reduces this risk. Using 16S rRNA gene sequencing, we undertook a prospective study in women at risk of preterm birth (n = 161) to assess (1) the relationship between vaginal microbiota and cervical length in the second trimester and preterm birth risk and (2) the impact of vaginal progesterone on vaginal bacterial communities in women with a short cervix. RESULTS: Lactobacillus iners dominance at 16 weeks of gestation was significantly associated with both a short cervix <25 mm (n = 15, P < 0.05) and preterm birth <34+0 weeks (n = 18; P < 0.01; 69% PPV). In contrast, Lactobacillus crispatus dominance was highly predictive of term birth (n = 127, 98% PPV). Cervical shortening and preterm birth were not associated with vaginal dysbiosis. A longitudinal characterization of vaginal microbiota (<18, 22, 28, and 34 weeks) was then undertaken in women receiving vaginal progesterone (400 mg/OD, n = 25) versus controls (n = 42). Progesterone did not alter vaginal bacterial community structure nor reduce L. iners-associated preterm birth (<34 weeks). CONCLUSIONS: L. iners dominance of the vaginal microbiota at 16 weeks of gestation is a risk factor for preterm birth, whereas L. crispatus dominance is protective against preterm birth. Vaginal progesterone does not appear to impact the pregnancy vaginal microbiota. Patients and clinicians who may be concerned about "infection risk" associated with the use of a vaginal pessary during high-risk pregnancy can be reassured.
Assuntos
Medida do Comprimento Cervical , Lactobacillus/efeitos dos fármacos , Microbiota/efeitos dos fármacos , Gravidez de Alto Risco/efeitos dos fármacos , Nascimento Prematuro/prevenção & controle , Progesterona/uso terapêutico , Vagina/microbiologia , Adulto , Carga Bacteriana/efeitos dos fármacos , Colo do Útero/fisiologia , Estudos Transversais , Disbiose/induzido quimicamente , Feminino , Humanos , Lactobacillus/classificação , Lactobacillus/genética , Pessários/efeitos adversos , Gravidez , Resultado da Gravidez , Estudos Prospectivos , RNA Ribossômico 16S/genética , Adulto JovemRESUMO
BACKGROUND: Preeclampsia and intrauterine fetal growth restriction (IUGR) are two of the most common causes of maternal and perinatal morbidity and mortality. Current methods of predicting those at most risk of these conditions remain relatively poor, and in clinical practice past obstetric history remains the most commonly used tool. Aspirin and, in women at risk of preeclampsia only, calcium have been demonstrated to have a modest effect on risk reduction. Several observational studies and randomised trials suggest that low molecular weight heparin (LMWH) therapy may confer some benefit. METHODS/DESIGN: This is a multicentre open label randomised controlled trial to determine the effect of the LMWH, enoxaparin, on the prevention of recurrence of preeclampsia and/or IUGR in women at high risk due to their past obstetric history in addition to standard high risk care for all participants. INCLUSION CRITERIA: A singleton pregnancy >6+0 and <16+0 weeks gestation with most recent prior pregnancy with duration >12 weeks having; (1) preeclampsia delivered <36+0 weeks, (2) Small for gestational age (SGA) infant <10th customised birthweight centile delivered <36+0 weeks or, (3) SGA infant ≤3rd customised birthweight centile delivered at any gestation. Randomisation is stratified for maternal thrombophilia status and women are randomly assigned to 'standard high risk care' or 'standard high risk care' plus enoxaparin 40 mg from recruitment until 36+0 weeks or delivery, whichever occurs sooner. Standard high risk care includes the use of aspirin 100 mg daily and calcium 1000-1500 mg daily (unless only had previous SGA with no preeclampsia). The primary outcome is preeclampsia and/or SGA <5th customised birthweight centile. Analysis will be by intention to treat. DISCUSSION: The EPPI trial has more focussed and clinically relevant inclusion criteria than other randomised trials with a more restricted composite primary outcome. The inclusion of standard use of aspirin (and calcium) for all participants will help to ensure that any differences observed in outcome are likely to be related to enoxaparin use. These data will make a significant contribution to future meta-analyses and systematic reviews on the use of LMWH for the prevention of placental mediated conditions. TRIAL REGISTRATION: ACTRN12609000699268 Australian New Zealand Clinical Trials Registry. Date registered 13/Aug/2009 (prospective registration).
Assuntos
Anticoagulantes/administração & dosagem , Enoxaparina/administração & dosagem , Retardo do Crescimento Fetal/prevenção & controle , Pré-Eclâmpsia/prevenção & controle , Gravidez de Alto Risco/efeitos dos fármacos , Adulto , Protocolos Clínicos , Feminino , Idade Gestacional , Humanos , Recém-Nascido Pequeno para a Idade Gestacional , Gravidez , Resultado da Gravidez , Resultado do Tratamento , Adulto JovemRESUMO
The presented clinical example convincingly demonstrates the efficacy of dydrogesterone (30 mg) in the prevention of severe preeclampsia in a high-risk patient (early development of preeclampsia and preterm Cesarean section in her first pregnancy, arterial hypertension). This case suggests using dydrogesterone as an option to prevent preeclampsia, as previously shown in a prospective randomized study.
Assuntos
Didrogesterona/uso terapêutico , Pré-Eclâmpsia/prevenção & controle , Gravidez de Alto Risco/efeitos dos fármacos , Progestinas/uso terapêutico , Adulto , Feminino , Humanos , Recém-Nascido , Gravidez , Resultado da GravidezRESUMO
OBJECTIVES: To perform a neurophysiological follow-up at 48 or 60 months of age in children exposed prenatally to progesterone compared with a placebo and evaluate their medical histories up to 8 years of age. METHODS: In this study, Danish participants of the PREDICT study, including 989 surviving children from 498 twin pregnancies, were followed-up. PREDICT was a placebo-controlled randomized clinical trial examining the effect of progesterone for prevention of preterm delivery in unselected twin pregnancies. Medical histories of the children were reviewed and neurophysiological development was evaluated by the parent-completed Ages and Stages Questionnaire (ASQ) at either 48 or 60 months after the estimated date of delivery. We used the method of generalized estimating equation to account for the correlation within twins. RESULTS: A total of 492 children had been exposed prenatally to progesterone and 497 to placebo. There was no difference in the number of admissions to or length of stay in hospital between the treatment groups, and we found no overall difference in the rates of diagnoses made. However, the odds ratios (ORs) for a diagnosis concerning the heart was 1.66 (95% CI, 0.81-3.37), favoring placebo, among all children, 2.38 (95% CI, 1.07-5.30) in dichorionic twins and 8.19 (95% CI, 1.02-65.6) in all children when excluding diagnoses made at outpatient clinic visits. ASQ scores were available for 437 children (progesterone, n = 225; placebo, n = 212). Mean ASQ score was slightly higher in the progesterone group compared with the placebo group (P = 0.03). In dichorionic twins, the risk of having a low ASQ score (< 10(th) centile) was decreased in the progesterone group (OR, 0.34 (95% CI, 0.14-0.86)). CONCLUSION: Second- and third-trimester exposure of the fetus to progesterone does not seem to have long-term harmful effects during childhood, but future studies should focus on cardiac disease in the child. Copyright © 2016 ISUOG. Published by John Wiley & Sons Ltd.
Assuntos
Gravidez de Alto Risco/efeitos dos fármacos , Nascimento Prematuro/prevenção & controle , Efeitos Tardios da Exposição Pré-Natal/fisiopatologia , Progesterona/administração & dosagem , Progestinas/administração & dosagem , Administração Intravaginal , Adulto , Criança , Desenvolvimento Infantil , Pré-Escolar , Parto Obstétrico , Dinamarca/epidemiologia , Feminino , Seguimentos , Idade Gestacional , Humanos , Lactente , Gravidez , Nascimento Prematuro/tratamento farmacológico , Efeitos Tardios da Exposição Pré-Natal/epidemiologia , GêmeosRESUMO
As desordens hipertensivas na gestação, em especial a pré-eclâmpsia (PE), são consideradas, nos países em desenvolvimento, a maior causa de morbimortalidade tanto materna quanto perinatal. Com objetivo de alcançar maior entendimento da fisiopatologia da PE e de evitar as manifestações clínicas desta doença e suas consequências, foram realizadas pesquisas relacionadas à suplementação de substâncias que atuariam na fisiopatologia, em especial examinando o uso do ácido acetilsalicílico (AAS). O uso de AAS em baixas doses em gestantes com alto risco de desenvolver PE quando iniciado na 16ª semana de gestação, ou mesmo antes, pode ser considerado importante avanço devido aos resultados observados em estudos relatando boa eficácia e redução do risco de morte perinatal, de restrição de crescimento intrauterino e de nascimento pré-termo.(AU)
Hypertensive disorders in pregnancy, particularly preeclampsia (PE), are considered a major cause of maternal and perinatal morbidity and mortality in developing countries. With the objetive of improving the knowledge about the pathophysiology of PE, and to avoid the clinical manifestations and consequences of this disease, several studies related with the supplementation of acetylsalicylic acid (AAS) on the PE pathophysiology have been performed. The use of low doses of AAS starting at or before week 16 can be considered an important advance in reducing the risk of perinatal death, intrauterine growth restriction and preterm birth.(AU)
Assuntos
Humanos , Feminino , Gravidez , Pré-Eclâmpsia/fisiopatologia , Pré-Eclâmpsia/prevenção & controle , Aspirina/uso terapêutico , Gravidez de Alto Risco/efeitos dos fármacos , Placentação/efeitos dos fármacos , Ensaios Clínicos Controlados Aleatórios como Assunto , Metanálise como Assunto , Eficácia , Trabalho de Parto Prematuro/prevenção & controleRESUMO
Although pregnancy after kidney transplantation has been considered as high risk for maternal and fetal complications, it can be successful in properly selected patients. It is well known that pregnancy can induce changes in the plasma concentrations of some drugs; however, there has been very limited information about tacrolimus pharmacokinetics during pregnancy. In this study, we evaluated the tacrolimus doses, blood levels, and the outcomes of pregnancies in kidney allograft recipients. From 2004 to 2014, we found 16 pregnancies in 12 kidney allograft recipients at our center. We reviewed the files and data reports including fetal outcomes, graft function, complications, tacrolimus trough levels, and doses. We analyzed the tacrolimus trough levels and doses before pregnancy, during pregnancy (monthly), and in the postpartum period. Throughout the pregnancy, we aimed to achieve tacrolimus trough levels between 4 and 7 ng/mL. All patients were on triple immunosuppression, including tacrolimus, azathioprine, and prednisolone. In total, 11 of 16 (68.7%) pregnancies were successful, with a mean weight gain of 12.5 ± 1.66 kg. One patient developed gestational diabetes mellitus and 2 had preeclampsia. Although 5 of 11 babies were found to have low birth weight, 4 of these were premature. Two patients lost their grafts, 1 due to acute rejection and the second due to progression of chronic allograft dysfunction. We have shown that tacrolimus doses need to be significantly increased to keep appropriate trough levels during pregnancy (the doses: before, 3.20 ± 0.9 mg/day; first trimester, 5.03 ± 1.5; second trimester, 6.50 ± 1.8; third trimester, 7.30 ± 2.3; post-partum, 3.5 ± 0.9). In conclusion, the dose of tacrolimus needs to be increased to provide safe and stable tacrolimus trough levels during pregnancy. Although pregnancy can be successful in most cases, it should be kept in mind that there is an increased risk of maternal and fetal complications, including allograft loss, low birth weight, spontaneous abortus, and preeclampsia.
Assuntos
Imunossupressores/administração & dosagem , Transplante de Rim , Gravidez de Alto Risco/efeitos dos fármacos , Tacrolimo/administração & dosagem , Adulto , Azatioprina/administração & dosagem , Contraindicações , Relação Dose-Resposta Imunológica , Feminino , Humanos , Terapia de Imunossupressão , Lactente , Prednisolona/administração & dosagem , Gravidez , Complicações na Gravidez/epidemiologia , Complicações na Gravidez/prevenção & controle , Resultado da Gravidez , Gravidez de Alto Risco/sangueAssuntos
Antioxidantes/uso terapêutico , Ácido Ascórbico/uso terapêutico , Cálcio da Dieta/uso terapêutico , Trabalho de Parto Prematuro/prevenção & controle , Pré-Eclâmpsia/prevenção & controle , Suplementos Nutricionais , Feminino , Humanos , Mães/educação , Gravidez , Resultado da Gravidez , Gravidez de Alto Risco/efeitos dos fármacosRESUMO
OBJECTIVE: To assess cerclage benefit in women with short cervix also receiving 17-α-hydroxyprogesterone caproate (17P) to prevent recurrent preterm birth (PTB). METHODS: Secondary analysis of a multicenter trial of ultrasound-indicated cerclage for shortened cervical length (CL). Women with prior spontaneous PTB at 16-33 6/7 weeks, singleton gestation and CL < 25 mm between 16 and 22 6/7 weeks were counseled on use of 17P and randomized to cerclage or no cerclage. Outcomes of women who received 17P were analyzed by randomization group. Primary outcome was PTB < 35 weeks. RESULTS: 99 women received 17P: 47 cerclage; 52 no cerclage. Rates of PTB < 35 weeks were similar, 30% for cerclage and 38% for no cerclage (aOR 0.64 (0.27-1.52)). In women with CL < 15 mm, PTB < 35 weeks was reduced for the cerclage group (17% vs. 75%, p = 0.02). However, this difference was nullified after controlling for total progesterone doses received (p = 0.40). CONCLUSIONS: Cerclage was shown not to offer additional benefit for the prevention of recurrent PTB in women with short CL < 25 mm receiving 17P, but the sample size is insufficient for a definite conclusion given the 36% nonsignificant decrease in the odds of PTB < 35 weeks. Cerclage may further offer substantial benefit to women with very short CL < 15 mm and further study is needed.